Summer Note 

​​​

As we near the end of summer, I wanted to take a moment to write you a note. Over the last quarter, we have been quite busy—meeting new colleagues and reconnecting with old friends and collaborators. This means we have many updates and announcements to share with you in the coming months.  However, I am thrilled to share some exciting news from SMDG here.

​

We are thrilled to announce that SMDG has been nominated in two prestigious categories at the Pharma Industry Awards UK 2024. Our team has been recognized for the Research and Development Achievement Award for our work on pioneering therapeutic platforms, specifically NanoLigand Carriers. This nomination is a testament to the impressive efforts our team has made over the last few years, and we extend our gratitude to the Pharma Industry Awards judges for acknowledging our therapeutic platform and research.

​

We are also proud to have been shortlisted as a finalist in the Women in Pharma Award category. I am truly honored to be recognized as a finalist for this award, which highlights the often tireless and sometimes underappreciated work that women contribute to the pharma industry.

 

Additionally, we are delighted to welcome Dr. Christy Hunter as our new Director of Chemistry. Dr. Hunter brings an impressive depth of expertise to our team. He is not only an exceptional scientist but also an inspiring mentor and educator. As a pharmacist, chartered chemist, and a Fellow of both the Royal Pharmaceutical Society and the Royal Society of Chemistry, he has built a remarkable career spanning 25 years. His work focuses on the intersection of pharmacy, chemistry, and pharmaceutical sciences, with wide-ranging applications in drug delivery and nanomedicine.

Dr. Hunter’s prolific contributions to the field include over 100 research publications. He earned his Doctor of Philosophy in Bio-Organic Chemistry from the University of Sussex under the guidance of Nobel Laureate Prof. Sir John Cornforth.

​

We are also pleased to welcome Mr. Theo Godfrey to our Business Advisory and Patient Outreach Board. Theo is a corporate and venture capital lawyer and a Partner at CMS Cameron McKenna Nabarro Olswang LLP in London. Much of his practice is focused on transactions within the life sciences sector. He is a passionate advocate for research and funding related to rare pediatric diseases, and his expertise will be invaluable as we continue to expand our impact.

​

In the coming months, we will be focused on fundraising efforts to advance our life-saving and disease-modifying therapies from the lab to the clinic, and ultimately to the patients who need them. We will also be sharing more updates about our partnerships and projects. To keep you informed, we are enhancing our website and revamping our social media presence. As part of this effort, we have closed our Twitter/X account and are launching a new Instagram account. Please follow us on LinkedIn and Instagram for the latest news and developments.

​

As always, our greatest focus and commitment is bringing life-saving therapies to patients. Every day, we strive to ensure that our work delivers tangible benefits to their lives. We invite you to join our mission, support us, and partner with us on this journey.

Feel free to reach out and connect with us at any of the upcoming meetings and events this year.​

​

Shadi 

​

September  2024

​

​

​